Objective To review clinical trial data for incretin therapies approved or in late-stage
development for overweight or obesity, along with clinical implications of these therapies …

Simple Summary In this review paper, we outline the role of GLP-1-RAs in potentially
influencing PCa development and progression. While GLP-1-RAs show promise in inhibiting …

Introduction Semaglutide, a glucagon-like peptide-1 receptor agonist, is associated with
significant weight loss, yet its impact on lean body mass remains insufficiently understood …

Metabolic disorders such as type 2 diabetes, fatty liver disease, hyperlipidemia, and obesity
commonly co-occur but clinical treatment options do not effectively target all disorders …

G protein-coupled receptors (GPCRs) have a critical role in energy homeostasis,
contributing to food intake, energy expenditure and glycaemic control. Dysregulation of …

Simple Summary This review mainly focuses on epigenetic changes in a few selective
genes associated with insulin insensitivity in the periphery and how this peripheral insulin …

BackgroundWeight gain and associated metabolic complications are increasingly prevalent
among people with HIV (PWH). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are …

Objectives There have been conflicting reports concerning an increased risk of pancreatic
cancer (PC) in new users of glucagon-like peptide-1 agonists (GLP-1As). We aimed to …

Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)
are incretins that regulate postprandial glucose regulation, stimulating insulin secretion from …

Glucagon-like peptide-1 (GLP-1) is involved in a range of central and peripheral pathways
related to appetitive behavior. Hence, this study explored the effects of glucagon-like peptide …